Efficacy and safety of 2-drug regime dolutegravir/lamivudine in pregnancy and breastfeeding – clinical implications and perspectives
Although 3DR remains the preferred therapy during pregnancy and breastfeeding, this case indicates that DTG/3TC may be an effective alternative for patients experiencing intolerance or poor adherence to 3DR. Further studies are needed to explore the impact of pharmacokinetic changes in pregnancy on 2DR efficacy and to confirm its safety and role in preventing MTCT.
Authors
- Maria Hoeltzenbein (ORCID: https://orcid.org/0000-0002-2451-4247)
- Katharina Weizsäcker
- Irena Rohr
- Cornelia Feiterna‐Sperling (ORCID: https://orcid.org/0000-0003-4171-1098)
- Charlotte K. Metz (ORCID: https://orcid.org/0000-0003-4551-4075)
- Christoph K. Weber
Institutions
- Humboldt-Universität zu Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal of Perinatal Medicine
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1515/jpm-2024-0304
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00